Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
On this final Oncology Onward episode of 2023, cohosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, talk with Penn Medicine’s Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation. Their conversation encapsulates much of what has been discussed in the oncology space in the past year, from the unique perspective of academic medicine: the importance of collaboration between academic medical centers and community oncology practices and testing innovative cancer care delivery in academic and community settings to have the greatest impact on patients.
“If we can only show that a certain innovation works at Penn Medicine or an academic practice, it's very limited—it's useful, but it's very limited,” Bekelman says. “If we want to demonstrate as part of our mandate to generalize knowledge across the country, we have to be able to extend programs into the community, learn from the community, test things that are working in the community in academic environments, create a bidirectional approach that allows for expertise from both systems to create the best possible opportunities for patients with cancer.”
For interview audio:
Listen above or on one of these podcast services:
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Workers Facing Greater Economic Hardship More Likely to Report Poor Health
June 2nd 2025US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to report fair or poor health, underscoring persistent disparities in worker well-being.
Read More
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More